研究実績

Comparing five-weekly S-1 plus cisplatin with tri-weekly capecitabine plus cisplatin in patients with HER2 negative recurrent gastric cancer after S-1 adjuvant therapy or chemotherapy naïve advanced gastric cancer: a pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials

Jin Matsuyama, Hisato Kawakami, Kazumasa Fujitani, Yusuke Akamaru, Shigeyuki Tamura, Shunji Endo, Yutaka Kimura, Youichi Makari, Takao Tamura, Naotoshi Sugimoto,Daisuke Sakai, Toshimasa Tsujinaka1, Masahiro Goto, Yukinori Kurokawa, Toshio Shimokawa, and Taroh Satoh ASCO-GI 2020, San-Francisco, USA,23-25 Jan 2020

前の記事 次の記事 一覧ページへ戻る